Staidson (Beijing) BioPharmaceuticals Co

Staidson (Beijing) BioPharmaceuticals Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Staidson (Beijing) BioPharmaceuticals Co (300204.SZ) as of Oct 17, 2026 is 260.17 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 60.21 % — a change of 332.10% (higher).

FCF Conversion

260.17 %

YoY

332.10%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Staidson (Beijing) BioPharmaceuticals Co is 2025 260.17 % . FCF Conversion Rate (FCF/EBITDA) of Staidson (Beijing) BioPharmaceuticals Co was 2024 60.21 % . It decreases by 332.10% higher compared to the previous year.

The Staidson (Beijing) BioPharmaceuticals Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
51.93 CNY
Jan 1, 2019
-57.02 CNY
Jan 1, 2020
122.89 CNY
Jan 1, 2021
158.88 CNY
Jan 1, 2022
117.82 CNY
Jan 1, 2023
65.09 CNY
Jan 1, 2024
60.21 CNY
Jan 1, 2025
260.17 CNY
The Staidson (Beijing) BioPharmaceuticals Co FCF Conversion history
YEARFCF ConversionYoY
260.17 %+332.10%
60.21 %-7.49%
65.09 %-44.76%
117.82 %-25.84%
158.88 %+29.29%
122.89 %-315.52%
-57.02 %-209.79%
51.93 %-39.85%
86.34 %+19.35%
72.34 %-26.26%
98.09 %-0.43%
98.52 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Staidson (Beijing) BioPharmaceuticals Co Stock analysis

What does Staidson (Beijing) BioPharmaceuticals Co do? Staidson Beijing BioPharmaceuticals Co Ltd is a leading biopharmaceutical company based in Beijing, China. The company has a long history and a wide range of products and services that make it an important player in the biotechnology field. Staidson (Beijing) BioPharmaceuticals Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Staidson (Beijing) BioPharmaceuticals Co stock

FCF Conversion Rate (FCF/EBITDA) of Staidson (Beijing) BioPharmaceuticals Co is 260.17 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Staidson (Beijing) BioPharmaceuticals Co changed from 60.21 % to 260.17 %, representing a 332.10% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Staidson (Beijing) BioPharmaceuticals Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Staidson (Beijing) BioPharmaceuticals Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Staidson (Beijing) BioPharmaceuticals Co

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Staidson (Beijing) BioPharmaceuticals Co